Client News
Roquefort Therapeutics plc: Director/PDMR ShareholdingRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, advises that
Stephen West, Executive Chairman has purchased ordinary shares in the Company in the market, as detailed below:
|
Name |
Number of Ordinary Shares |
Average Price Paid Per Share |
Total Consideration Paid |
|
Stephen West |
150,000 |
10.36 pence |
£15,542.10 |
Following the above purchase of shares, Mr West holds interests in the following Company securities:
|
Name |
Number of Ordinary Shares Held |
% of Issued Share Capital |
Number of Warrants Held |
|
Stephen West |
4,550,000 |
6.33 % |
7,500,000 |
4,399,000 of Mr West’s shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.
https://www.londonstockexchange.com/news-article/ROQ/director-pdmr-shareholding/15294129
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
CLIENT AREA
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.